A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 11,173 shares of GALT stock, worth $11,619. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,173
Holding current value
$11,619
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.04 - $2.86 $22,792 - $31,954
11,173 New
11,173 $30,000

Others Institutions Holding GALT

About GALECTIN THERAPEUTICS INC


  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $61.8M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Mirae Asset Global Etfs Holdings Ltd. Portfolio

Follow Mirae Asset Global Etfs Holdings Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Etfs Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Etfs Holdings Ltd. with notifications on news.